growth factor-mediated phosphorylation of AF-1 might supplant AF-2 as the primary route of ER recruitment of co-activators during activation of ER target genes in tamoxifen-resistant cells.
GIV makes these cancer cells specifically resistant to estrogen-targeted therapies, such as the drug Tamoxifen. The researchers hope this understanding of the mechanism of cancer cell survival ...
This is a type fuelled by the hormone oestrogen which can stimulate cancer cells to grow and divide. Every patient received treatments such as tamoxifen or aromatase inhibitors which block the ...
Tamoxifen has an antiresorptive effect in bone and stimulates proliferation of endometrial cells. It causes a two- to three-fold increase in deep venous thrombosis and pulmonary embolism and a ...
Hormonal cancer medications even work as preventative medicine: the FDA has recently approved the use of Tamoxifen in women ... agents directly to tumor cells, avoiding the "fallout" damage ...